HIV-1 and the host cell: An intimate association

Trends in Microbiology

Volumn 12, Issue 4, 2004, Pages 170-177

  Freed, Eric O ^a  

^a NATIONAL CANCER INSTITUTE   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

TRANSACTIVATOR PROTEIN;

GENETIC CODE; GENOME ANALYSIS; HOST CELL; HUMAN IMMUNODEFICIENCY VIRUS 1; MEMBRANE FUSION; NONHUMAN; PRIORITY JOURNAL; RETROVIRUS; REVIEW; RNA TRANSCRIPTION; VIRUS ASSEMBLY; VIRUS CELL INTERACTION; VIRUS GENE; VIRUS REPLICATION; VIRUS RESISTANCE;

ANTIVIRAL AGENTS; GENES, VIRAL; HIV-1; MACROPHAGES; MEMBRANE FUSION; RECEPTORS, HIV; RNA, VIRAL; T-LYMPHOCYTES; TRANSCRIPTION, GENETIC; VIRUS ASSEMBLY; VIRUS INTEGRATION; VIRUS REPLICATION;

HUMAN IMMUNODEFICIENCY VIRUS; HUMAN IMMUNODEFICIENCY VIRUS 1; RNA VIRUSES; UNIDENTIFIED RETROVIRUS;

EID: 1642289565     PISSN: 0966842X     EISSN: None     Source Type: Journal    
DOI: 10.1016/j.tim.2004.02.001     Document Type: Review

References (70)

1. Goff S. Retroviridae: the retroviruses and their replication. Knipe D.M., Howley P.M. Fields Virology. 4th edn:2001;1871-1940 Lippincott Williams and Wilkins.
2. Freed E.O., Martin M.A. HIVs and their replication Knipe D.M., Howley P.M. Fields Virology. HIVs and their replication 4th edn:2001;1971-2041 Lippincott Williams and Wilkins.
3. Berger E.A., et al. Chemokine receptors as HIV-1 coreceptors: roles in viral entry, tropism, and disease. Annu. Rev. Immunol. 17:1999;657-700.
4. Manes S., et al. Membrane raft microdomains mediate lateral assemblies required for HIV-1 infection. EMBO Rep. 1:2000;190-196.
5. Liao Z., et al. Lipid rafts and HIV pathogenesis: host membrane cholesterol is required for infection by HIV type 1. AIDS Res. Hum. Retroviruses. 17:2001;1009-1019.
6. Nguyen D.H., Taub D. CXCR4 function requires membrane cholesterol: implications for HIV infection. J. Immunol. 168:2002;4121-4126.
7. Popik W., et al. Human immunodeficiency virus type 1 uses lipid raft-colocalized CD4 and chemokine receptors for productive entry into CD4(+) T cells. J. Virol. 76:2002;4709-4722.
8. Viard M., et al. Role of cholesterol in human immunodeficiency virus type 1 envelope protein-mediated fusion with host cells. J. Virol. 76:2002;11584-11595.
9. Percherancier Y., et al. HIV-1 entry into T-cells is not dependent on CD4 and CCR5 localization to sphingolipid-enriched, detergent-resistant, raft membrane domains. J. Biol. Chem. 278:2003;3153-3161.
10. Geijtenbeek T.B., et al. DC-SIGN, a dendritic cell-specific HIV-1-binding protein that enhances trans-infection of T cells. Cell. 100:2000;587-597.
11. Geijtenbeek T.B., van Kooyk Y. DC-SIGN: a novel HIV receptor on DCs that mediates HIV-1 transmission. Curr. Top. Microbiol. Immunol. 276:2003;31-54.
12. McDonald D., et al. Recruitment of HIV and its receptors to dendritic cell-T cell junctions. Science. 300:2003;1295-1297.
13. Sheehy A.M., et al. Isolation of a human gene that inhibits HIV-1 infection and is suppressed by the viral Vif protein. Nature. 418:2002;646-650.
14. Harris R.S., et al. DNA deamination mediates innate immunity to retroviral infection. Cell. 113:2003;803-809.
15. Lecossier D., et al. Hypermutation of HIV-1 DNA in the absence of the Vif protein. Science. 300:2003;1112.
16. Mangeat B., et al. Broad antiretroviral defence by human APOBEC3G through lethal editing of nascent reverse transcripts. Nature. 424:2003;99-103.
17. Mariani R., et al. Species-specific exclusion of APOBEC3G from HIV-1 virions by Vif. Cell. 114:2003;21-31.
18. Zhang H., et al. The cytidine deaminase CEM15 induces hypermutation in newly synthesized HIV-1 DNA. Nature. 424:2003;94-98.
19. Stopak K., et al. HIV-1 Vif blocks the antiviral activity of APOBEC3G by impairing both its translation and intracellular stability. Mol. Cell. 12:2003;591-601.
20. Lilly F. Susceptibility to two strains of Friend leukemia virus in mice. Science. 155:1967;461-462.
21. Lilly F. Fv-2: identification and location of a second gene governing the spleen focus response to Friend leukemia virus in mice. J. Natl. Cancer Inst. 45:1970;163-169.
22. Odaka T., Yamamoto T. Inheritance of susceptibility to Friend mouse leukemia virus. 11. Spleen foci method applied to test the susceptibility of crossbred progeny between a sensitive and a resistant strain. Jpn. J. Exp. Med. 35:1965;311-314.
23. DesGroseillers L., Jolicoeur P. Physical mapping of the Fv-1 tropism host range determinant of BALB/c murine leukemia viruses. J. Virol. 48:1983;685-696.
24. Kozak C.A., Chakraborti A. Single amino acid changes in the murine leukemia virus capsid protein gene define the target of Fv1 resistance. Virology. 225:1996;300-305.
25. Best S., et al. Positional cloning of the mouse retrovirus restriction gene Fv1. Nature. 382:1996;826-829.
26. Towers G., et al. A conserved mechanism of retrovirus restriction in mammals. Proc. Natl. Acad. Sci. U. S. A. 97:2000;12295-12299.
27. Bieniasz P.D. Restriction factors: a defense against retroviral infection. Trends Microbiol. 11:2003;286-291.
28. Lee M.S., Craigie R. Protection of retroviral DNA from autointegration: involvement of a cellular factor. Proc. Natl. Acad. Sci. U. S. A. 91:1994;9823-9827.
29. Farnet C.M., Bushman F.D. HIV-1 cDNA integration: requirement of HMG I(Y) protein for function of preintegration complexes in vitro. Cell. 88:1997;483-492.
30. Chen H., Engelman A. The barrier-to-autointegration protein is a host factor for HIV type 1 integration. Proc. Natl. Acad. Sci. U. S. A. 95:1998;15270-15274.
31. Li L., et al. Modulation of activity of Moloney murine leukemia virus preintegration complexes by host factors in vitro. J. Virol. 72:1998;2125-2131.
32. Suzuki Y., Craigie R. Regulatory mechanisms by which barrier-to- autointegration factor blocks autointegration and stimulates intermolecular integration of Moloney murine leukemia virus preintegration complexes. J. Virol. 76:2002;12376-12380.
33. Lin C.W., Engelman A. The barrier-to-autointegration factor is a component of functional human immunodeficiency virus type 1 preintegration complexes. J. Virol. 77:2003;5030-5036.
34. Li L., et al. Retroviral cDNA integration: stimulation by HMG I family proteins. J. Virol. 74:2000;10965-10974.
35. Beitzel B., Bushman F. Construction and analysis of cells lacking the HMGA gene family. Nucleic Acids Res. 31:2003;5025-5032.
36. Kalpana G.V., et al. Binding and stimulation of HIV-1 integrase by a human homolog of yeast transcription factor SNF5. Science. 266:1994;2002-2006.
37. Cherepanov P., et al. HIV-1 integrase forms stable tetramers and associates with LEDGF/p75 protein in human cells. J. Biol. Chem. 278:2003;372-381.
38. Maertens G., et al. LEDGF/p75 is essential for nuclear and chromosomal targeting of HIV-1 integrase in human cells. J. Biol. Chem. 278:2003;33528- 33539.
39. Alonso A., et al. Human chromosome 12 is required for optimal interactions between Tat and TAR of human immunodeficiency virus type 1 in rodent cells. J. Virol. 66:1992;4617-4621.
40. Wei P., et al. A novel CDK9-associated C-type cyclin interacts directly with HIV-1 Tat and mediates its high-affinity, loop-specific binding to TAR RNA. Cell. 92:1998;451-462.
41. Cullen B.R. Nuclear mRNA export: insights from virology. Trends Biochem. Sci. 28:2003;419-424.
42. Fornerod M., et al. CRM1 is an export receptor for leucine-rich nuclear export signals. Cell. 90:1997;1051-1060.
43. Reddy T.R., et al. Inhibition of HIV replication by dominant negative mutants of Sam68, a functional homolog of HIV-1 Rev. Nat. Med. 5:1999;635-642.
44. Li J., et al. Direct participation of Sam68, the 68-kilodalton Src-associated protein in mitosis, in the CRM1-mediated Rev nuclear export pathway. J. Virol. 76:2002;8374-8382.
45. Luban J., et al. Human immunodeficiency virus type 1 Gag protein binds to cyclophilins A and B. Cell. 73:1993;1067-1078.
46. Franke E.K., et al. Specific incorporation of cyclophilin A into HIV-1 virions. Nature. 372:1994;359-362.
47. Thali M., et al. Functional association of cyclophilin A with HIV-1 virions. Nature. 372:1994;363-365.
48. Towers G.J., et al. Cyclophilin A modulates the sensitivity of HIV-1 to host restriction factors. Nat. Med. 9:2003;1138-1143.
49. Nguyen D.H., Hildreth J.E. Evidence for budding of human immunodeficiency virus type 1 selectively from glycolipid-enriched membrane lipid rafts. J. Virol. 74:2000;3264-3272.
50. Lindwasser O.W., Resh M.D. Multimerization of human immunodeficiency virus type 1 Gag promotes its localization to barges, raft-like membrane microdomains. J. Virol. 75:2001;7913-7924.
51. Ono A., Freed E.O. Plasma membrane rafts play a critical role in HIV-1 assembly and release. Proc. Natl. Acad. Sci. U. S. A. 98:2001;13925-13930.
52. Lindwasser O.W., Resh M.D. Myristoylation as a target for inhibiting HIV assembly: unsaturated fatty acids block viral budding. Proc. Natl. Acad. Sci. U. S. A. 99:2002;13037-13042.
53. Gottlinger H.G., et al. Effect of mutations affecting the p6 gag protein on human immunodeficiency virus particle release. Proc. Natl. Acad. Sci. U. S. A. 88:1991;3195-3199.
54. Huang M., et al. p6Gag is required for particle production from full-length human immunodeficiency virus type 1 molecular clones expressing protease. J. Virol. 69:1995;6810-6818.
55. Freed E.O. Viral late domains. J. Virol. 76:2002;4679-4687.
56. Pornillos O., et al. Mechanisms of enveloped RNA virus budding. Trends Cell Biol. 12:2002;569-579.
57. Katzmann D.J., et al. Ubiquitin-dependent sorting into the multivesicular body pathway requires the function of a conserved endosomal protein sorting complex, ESCRT-I. Cell. 106:2001;145-155.
58. Babst M., et al. Escrt-III: an endosome-associated heterooligomeric protein complex required for mvb sorting. Dev. Cell. 3:2002;271-282.
59. Babst M., et al. Endosome-associated complex, ESCRT-II, recruits transport machinery for protein sorting at the multivesicular body. Dev. Cell. 3:2002;283-289.
60. Katzmann D.J., et al. Receptor downregulation and multivesicular-body sorting. Nat. Rev. Mol. Cell Biol. 3:2002;893-905.
61. Verplank L., et al. Tsg101, a homologue of ubiquitin-conjugating (E2) enzymes, binds the L domain in HIV type 1 Pr55Gag. Proc. Natl. Acad. Sci. U. S. A. 98:2001;7724-7729.
62. Garrus J.E., et al. Tsg101 and the vacuolar protein sorting pathway are essential for HIV-1 budding. Cell. 107:2001;55-65.
63. Demirov D.G., et al. Overexpression of the N-terminal domain of TSG101 inhibits HIV-1 budding by blocking late domain function. Proc. Natl. Acad. Sci. U. S. A. 99:2002;955-960.
64. Martin-Serrano J., et al. HIV-1 and Ebola virus encode small peptide motifs that recruit Tsg101 to sites of particle assembly to facilitate egress. Nat. Med. 7:2001;1313-1319.
65. Martin-Serrano J., et al. Role of ESCRT-I in retroviral budding. J. Virol. 77:2003;4794-4804.
66. Tanzi G.O., et al. Equine infectious anemia virus utilizes host vesicular protein sorting machinery during particle release. J. Virol. 77:2003;8440-8447.
67. Shehu-Xhilaga M., et al. Late domain dependent inhibition of equine infectious anemia virus budding. J. Virol. 78:2004;724-732.
68. Strack B., et al. AIP1/ALIX is a binding partner for HIV-1 p6 and EIAV p9 functioning in virus budding. Cell. 114:2003;689-699.
69. von Schwedler U.K., et al. The protein network of HIV budding. Cell. 114:2003;701-713.
70. Zimmerman C., et al. Identification of a host protein essential for assembly of immature HIV-1 capsids. Nature. 415:2002;88-92.